期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

甲状腺癌中BRAF^(V600E)突变的表达及意义 被引量：3

下载PDF
导出
摘要 甲状腺癌起源于滤泡细胞，是最常见的内分泌肿瘤，其组织学类型主要包括乳头状癌（PTC），滤泡状癌（FTC），未分化癌（ATC）和髓样癌（MTC），其中以PTC所占比例最大。丝裂原活化的蛋白激酶（MAPK）通路的激活与VIE的发生和进展有密切关系，
作者 曹艳 石光清 向谷良
机构地区 中南大学湘雅三医院核医学科
出处 《放射免疫学杂志》 CAS 2011年第5期599-600,共2页 Journal of Radioimmanology
关键词 BRAF^V600E 甲状腺癌 丝裂原活化的蛋白激酶 突变 内分泌肿瘤 组织学类型 滤泡细胞 乳头状癌
分类号 R736.1 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献23

  • 1Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell,1990,60:557-563.
  • 2Greco A,Pierotti MA, Bongarzone I, et al.TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas.Oncogene,1992,7:237-242.
  • 3Kroll TG,Sarraf P,Pecciarini L,et al.PAX8-PPAR gammal fusion in human thyroid carcinoma.Science,2000,289:1357-1360.
  • 4Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol,1990,4:1474-1479.
  • 5Zhu Z, Gandhi M,Nikiforava MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma.An unusually high prevalence of ras mutations.Am J Clin Pathol,2003,120:71-77.
  • 6Kimura ET,Nikiforava MN,Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cnacer Res,2003,63:1454-1457.
  • 7Soares P, Fonseca E, Wynford-Thomas D, et al. Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms. J Pathol,1998,185:71-78.
  • 8Xu X, Quiros RM, Gattuso P, et al.High prevalence of BRAF gene mutation in papillary thyroid carcinomas and tumor cell lines. Can Res,2003,63:4561-4567.
  • 9Delellis RA, Lloyd RV, Heitz PU, et al. World health organization classification of tumors: pathology and genetics, tumors of endocrine organs. Lyon: IARC Press, 2004.
  • 10FletcherCD 周庚寅 刘洪琪 张庆慧 译.肿瘤组织病理诊断[M].济南:山东科学技术出版社,2001..

共引文献29

同被引文献68

  • 1钱碧云,陈可欣,何敏,董淑芬,韩宏伟,雷蕾,王继芳.天津市区甲状腺癌流行状况调查[J].中国肿瘤临床,2005,32(4):218-221. 被引量：56
  • 2朱晓丽,周晓燕,朱雄增.甲状腺乳头状癌中BRAF^(V599E)点突变与RET/PTC融合基因的检测[J].中华病理学杂志,2005,34(5):270-274. 被引量：30
  • 3尹香利,张国昌,李锋,赵瑾,李洪安,梁伟华.MASA-PCR检测甲状腺乳头状癌中BRAF^(V600E)点突变的研究[J].石河子大学学报（自然科学版）,2005,23(5):551-555. 被引量：4
  • 4Kebebew E, Weng J, Bauer J, et al. The prevalence and prognos- tic value of BRAF mutation in thyroid cancer [ J]. Ann Surg, 2007,246 ( 3 ) :466-470.
  • 5Oler G, Cerutti JM. High prevalence of BRAF mutation in a Bra- zilian cohort of patients with sporadic papillary thyroid carcinomas : correlation with more aggressive phenotype and decreased expres- sion of iodidem etabolizing genes [ J ]. Cancer, 2009,115 ( 5 ) : 972 -980.
  • 6Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications [ J ]. Endocr Rev, 2007,28 ( 7 ) : 742 -762.
  • 7Kebebew E,Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer[ J]. Ann Surg,2007,246 ( 3 ) :466-471.
  • 8HUNDAHL S A, FLEMING I D, FREMGEN A M, et al. A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U. S., 1985-1995 [see commetns] [J]. Cancer, 1998, 83(12).. 2638-2648.
  • 9DOHA. N O, BALOCH Z, BANRI~VI Z, et al. Rapid communication: predominant intracellular overexpression of the Na(-~-)/I (-) symporter (NIS) in a large sampling of thyroid cancer easesEJ]. J Clin Endoerinol Metab, 2001, 86 (6) : 2697-2700.
  • 10IKAWA S, FUKUI M, UEYAMA Y, et al. B-raf, a new member of the raf family, is activated by DNA rearrangement[J]. Mol Cell Biol, 1988, 8(6) : 2651-2654.

引证文献3

二级引证文献17

放射免疫学杂志
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部